

**Activity Outline**  
**FDA Drug Topics: FDA's MedWatch Adverse Reporting Program – Opportunities to Collaborate**  
**March 13, 2018**  
**FDA**

**Series Description**

This series of educational webinars is designed to aid physicians, physician assistants, nurses, pharmacists, pharmacy technicians, students, and other healthcare professionals, to provide better patient care by knowing how to find relevant FDA regulatory information that will improve drug safety.

**Lecture Description**

This webinar will provide an overview of the Office of Health and Constituent Affairs, identify opportunities to collaborate and advance FDA public health messages and promote public involvement with FDA, describe the FDA MedWatch program, demonstrate how to report adverse events to MedWatch and how to obtain safety information.

**References**

- MedWatch: The FDA Safety Information and Adverse Event Reporting Program at <https://www.fda.gov/Safety/MedWatch/default.htm>
- MedWatchLearn at <https://www.accessdata.fda.gov/scripts/MedWatchLearn/>
- MEDWATCH Consumer Voluntary Reporting (FORM FDA 3500B) at <https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM349464.pdf>
- MedWatch Minute For Health Professionals at <https://www.fda.gov/Safety/MedWatch/ucm133050.htm>

**Series Objectives**

- Explain how to utilize FDA's Drug Information, medication safety resources, and regulatory guidances to improve delivery of patient care and optimize outcomes.
- Describe and inform health care providers of recent labeling, policy and regulatory changes which would impact prescribing and medication management to optimize patient care.

**Learning Objectives** After completion of this activity, the participant will be able to:

- Describe the FDA Office of Health and Constituent Affairs (OHCA)
- List ways to collaborate and be involved in FDA processes
- Identify adverse events and product problems that should be reported to FDA.
- Demonstrate how to submit a report to the FDA MedWatch Program.

**Target Audience**

This activity is intended for physicians, pharmacists, pharmacy technicians, and nurses.

**Agenda**

**Lecture 1 March 13, 2018**

Time	Topic	Speaker
1:00 - 2:00 PM	FDA's MedWatch Adverse Reporting Program – Opportunities to Collaborate	Steve Morin

**Continuing Education Accreditation**



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

## CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## CPE

This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-18-026-L04-P, and ACPE Universal Activity Number JA0002895-0000-18-026-L04-T for 1.00 contact hour(s).

## CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

## Requirements for Receiving CE Credit

**Physicians, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME:** participants must attest to their attendance and complete the final activity evaluation via the CE Portal ([ceportal.fda.gov](http://ceportal.fda.gov)). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

**Pharmacy participants:** partial credit cannot be awarded, therefore you must attend the entire activity to receive CPE credit. No exceptions. Pharmacists will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit.

## Important Note regarding completion of evaluations and receiving credit

Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 10 weeks after the last session of the activity to obtain their CE credit.

## Disclosure

### Faculty

- Morin, Steve, Health Programs Coordinator, FDA, Office of Health and Constituent Affairs - nothing to disclose

### Planning Committee

- Burke, Kara, PharmD, Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose
- DeFronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
- Giroux, Virginia, MSN, FNP-BC, Associate Director for Accreditation, FDA/CDER/OEP/DLOD - nothing to disclose
- Navin, Lesley, RN, MSN, CSO, FDA/CDER/DDI - nothing to disclose
- Weinstein, Edward, M.D., Ph.D., Medical Officer, CDER FDA *My spouse received Salary from EndoCentre of Baltimore for a role as Employee.*

### CE Consultation and the Accreditation Team

- Gorinson, Justin, B.S., CHES, ORISE Fellow, FDA/CDER/OEP/DLOD - nothing to disclose
- Giroux, Virginia, MSN, FNP-BC, Associate Director for Accreditation, FDA/CDER/OEP/DLOD - nothing to disclose
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose

## Registration Fee and Refunds

Registration is complimentary, therefore refunds are not applicable.